Improvements in clinical and patient-reported outcomes and durability of response with the targeted oral peptide icotrokinra in adolescents with moderate-to-severe plaque psoriasis

Soung J, et al. J Am Acad Dermatol. 2026;95(4):1103-1106.


Improvements in clinical and patient-reported outcomes and durability of response with the targeted oral peptide icotrokinra in adolescents with moderate-to-severe plaque psoriasis: One-year results from the ICONIC-LEAD randomized controlled trial

DOWNLOAD PUBLICATION